KBYPF — Stock Film
STOCK FILMSCENE 1/11KBYPF · $34.05
Stock Expert AI presents
KBYPF
Kobayashi Pharmaceutical Co., Ltd
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Kobayashi Pharmaceutical Co., Ltd. A quick introduction.

On the stock market since 2015, it operates in the everyday-essentials business. It has 3,615 employees. Now — the numbers.

on the stock market since 2015
3,615 employees
$2.5B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $2 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 2%

This is an established company with proven profits.

THE SALES TREND
Sales are moving sideways.

No real growth (2% a year).

$155B
2021
$166B
2022
$173B
2023
$166B
2024
$166B
2025
Cash on hand:
$0
Total debt:
$0
The cash outweighs the debt.

If every debt were paid off today, $70.0B would still be left in the vault — a solid cushion for hard times.

Every quarter, analysts set a profit bar.
How many of the last 8 did the company clear?
2 / 8
EXPECTATIONS MET OR BEATEN
2
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Nov 2025
Feb 2026
May 2026
2 TIMES IN THE LAST 8 QUARTERS
It misses the bar more often than not.
THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking8/10
A strong cash pile8/10
WEAK SPOTS
Heavy bets against the stock2/10
Growth has stalled4/10
WORTH WATCHING

Bets Against the Stock: The number of investors betting on a fall stands out.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 60% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Strong cash, light debt

There is $70.7B in the vault; even if every debt were paid off, $70.0B would remain.

2
THE BRIGHT SIDE · 2/2
Pays a steady dividend

It pays out $0.67 per share each year — regular cash for whoever holds the stock.

1
THE RISKS · 1/3
Sales are shrinking

Over the last 3 years, sales fell about 0% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.

2
THE RISKS · 2/3
Heavy bets against the stock

The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.

3
THE RISKS · 3/3
Growth has stalled

The sales tempo runs behind the sector. Council score: 4/10.

FINALE · THE GRADE
C
0 / 100 · MoonshotScore

On our five-subject report card, KBYPF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: KBYPF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film